Olympus Launches AI-Powered Endoscopy Apps in Europe
Olympus Europa SE & Co. KG has commercially launched the first three applications within its OLYSENSE CAD/AI portfolio. This suite of cloud-based, AI-supported apps aims to enhance clinical and operational performance in endoscopy, with initial sales in Germany, France, and the United Kingdom.
The OLYSENSE CAD/AI portfolio harnesses artificial intelligence to detect and characterise suspected tissues and lesions in endoscopy procedures. It consists of three CE-approved apps: CADDIE, CADU, and SMARTIBD.
CADDIE, a cloud-based AI for colonoscopy, has shown a 7.4% absolute increase in adenoma detection rate (ADR) compared to standard of care. A multi-centre randomised controlled trial demonstrated its potential for hard-to-detect and high-risk polyps.
CADU addresses Barrett's Esophagus by highlighting areas with the highest likelihood of dysplasia in endoscopy images. Meanwhile, SMARTIBD assists in the analysis of Ulcerative Colitis in line with the MAYO scoring.
The launch of these three applications marks the first step towards creating Olympus' intelligent endoscopy ecosystem. The portfolio's potential to improve clinical outcomes and operational efficiency is evident, with CADDIE's proven impact on adenoma detection rate. The CE-approved apps are now available in Germany, France, and the United Kingdom.
